Abcellera Biologics Inc ABCL

$11.03 -0.09 (-0.81%)

Valuation

Market cap
3,631,992,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
2,695,600
Avg volume
4,310,924
Day's range
$10.81 – $11.40
Shares out
326,618,000
Stochastic %K
12%
Beta
1.59
Analysts
Strong Buy
Price target
$17.92

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

SultanK Nov 18, 6:33 AM
$ABCL CEO on linkedin.com Bruce Booth at Atlas does a terrific annual rundown on what’s happening in biotech. Exciting to see AbCellera ’s ABCL635, a first-in-class antibody treatment for VMS (hot flashes) called out as one of 2026’s six most exciting new drugs. We couldn’t agree more(!) and see tremendous potential for a major breakthrough treatment in women’s health. And also very proud to see Xenon Pharmaceuticals Inc.’s Azatukelner, a Kv1.7 activator for focal seizures, named right beside us on the list. Congrats Ian Mortimer and the X-team! And, just case you weren’t watching, Vancouver is slowly but surely proving that we are a world-class center for innovation in drug development. 🇨🇦 Check out the full report here: https://lnkd.in/grVzDGRN
0 replies
Odoji Nov 17, 9:03 PM
$ABCL 💉
0 replies
CoffeeRocks Nov 17, 8:50 PM 0 replies
maestrodarkhorse Nov 17, 7:16 PM
$ABCL Execs keep buying, the CFO bought shares in the open market.. I have a feeling expedited FDA approval is coming.
2 replies
maestrodarkhorse Nov 17, 7:13 PM
$ABCL Love these emails! Andrew Booth, CFO of $ABCL , is loading up at ~$11. +8,600 shares for Andrew. No buys like insider buys after a 300% run.
1 replies
flymetothemoon2 Nov 17, 7:08 PM
$ABCL @erpy
0 replies
flymetothemoon2 Nov 17, 7:00 PM 0 replies
Buying_Low_Selling_High Nov 17, 6:59 PM
$ABCL Selling now is a mistake.
0 replies